Court Upholds FTC Order Against POM, But Scrutinizes Clinical Trial Requirement

The U.S. Court of Appeals for the District of Columbia Circuit on Jan. 30 issued a ruling largely upholding the FTC’s 2012 order against POM, but said the agency’s argument fails “scrutiny insofar as it categorically requires two RCTs for all disease-related claims.”